DURHAM, N.C. (PRWEB) January 25, 2018
STEM CELLS Translational Medicine (SCTM) named Philippe Lysy, M.D., Ph.D., the STEM CELLS Translational Medicine’s Young Investigator of 2017 for his exploration of new sources of cells capable of conversion into insulin-secretors. The award fosters advancements in the field of stem cells and regenerative medicine by honoring a young researcher who is principle author of an article published in SCTM that is deemed to have the most impact and to push the boundaries of novel and insightful research.
Dr. Lysy’s data describe a new, reliable, and fast procedure in adult human pancreatic cells to generate clinically relevant amounts of new β cells with potential to reverse diabetes. The paper was published in the November 2016 issue of SCTM.
“The potential to reverse diabetes with this β-cell replacement therapy could change the lives of 415 million people worldwide living with the disease,” said Anthony Atala, M.D., Editor-in-Chief of SCTM and director of the Wake Forest Institute for Regenerative Medicine. “This research data suggests a reliable and fast procedure to generate clinically relevant amounts of new β-cells for translational studies and could potentially lead to other disease applications as well.”
Dr. Lysy is a professor at Université Catholique de Louvain (UCL) in Brussels, Belgium, where he heads up the pediatric endocrinology and diabetes service at Cliniques Universitaires Saint Luc and supervises a research team in the laboratory of pediatrics (IREC). He received both his M.D. (in 2003) and his Ph.D. (2008) from UCL. While finishing his formation in pediatrics, Dr. Lysy had the opportunity to spend two years as a postdoctoral fellow in the laboratory of Susan Bonner-Weir at Joslin Diabetes Center, Harvard Medical School (Boston), where he studied the role of human pancreatic ductal cells as progenitors in the setting of beta-cell replacement strategies.
The STEM CELLS Translational Medicine Young Investigator Award, which includes a $10,000 cash incentive, is co-sponsored by CIRM and Quintiles in cooperation with the Regenerative Medicine Foundation. Its winner is selected each year by the journal’s editorial board, made up of leading experts in the field of regenerative medicine worldwide.
Read the paper that helped Dr. Lysy earn the STEM CELLS Translational Medicine Young Investigator Award, titled "V-Maf Musculoaponeurotic Fibrosarcoma Oncogene Homolog A Synthetic Modified mRNA Drives Reprogramming of Human Pancreatic Duct-Derived Cells Into Insulin-Secreting Cells."
About STEM CELLS Translational Medicine: STEM CELLS Translational Medicine (SCTM), published by AlphaMed Press, is a monthly peer-reviewed publication dedicated to significantly advancing the clinical utilization of stem cell molecular and cellular biology. By bridging stem cell research and clinical trials, SCTM will help move applications of these critical investigations closer to accepted best practices.
About AlphaMed Press: Established in 1983, AlphaMed Press with offices in Durham, NC, San Francisco, CA, and Belfast, Northern Ireland, publishes two other internationally renowned peer-reviewed journals: STEM CELLS® (http://www.StemCells.com), celebrating its 36th year, is the world's first journal devoted to this fast paced field of research. The Oncologist® (http://www.TheOncologist.com), also a monthly peer-reviewed publication, entering its 23rd year, is devoted to community and hospital-based oncologists and physicians entrusted with cancer patient care. All three journals are premier periodicals with globally recognized editorial boards dedicated to advancing knowledge and education in their focused disciplines.
About Wiley: Wiley, a global company, helps people and organizations develop the skills and knowledge they need to succeed. Our online scientific, technical, medical and scholarly journals, combined with our digital learning, assessment and certification solutions, help universities, learned societies, businesses, governments and individuals increase the academic and professional impact of their work. For more than 200 years, we have delivered consistent performance to our stakeholders. The company's website can be accessed at http://www.wiley.com.